Xu et al. showed that elevated BMI, BSA, body weight, and basal metabolic rate are associated with more severe PsO and diminished treatment efficacy, especially for those treated with biologics. Authors investigated the associations of BMI, basal metabolic rate, BSA, and body weight with baseline PsO severity and therapeutic response across different treatment modalities.

Bennett et al, showed that tofacitinib treatment in adults with rheumatoid arthritis led to a significant increase in lower limb and thigh muscle volume, accompanied by rises in serum creatinine without evidence of renal impairment.